714 assets in Colorectal Cancer

Therapeutic assets addressing Colorectal Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Anlotinib Hydrochloride Capsules Colorectal Cancer	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	P1	C (36)
Anti-Cea Car-T Cells Colorectal Cancer	Changhai Hospital	P1	C (36)
asp5834 Colorectal Cancer	Astellas Pharma Inc	P1	C (36)
atp128 Colorectal Cancer	Amal Therapeutics	P1	C (36)
ava6103 Colorectal Cancer	Avacta Life Sciences Ltd	P1	C (36)
Bdc-3042 Colorectal Cancer	Bolt Biotherapeutics, Inc.	P1	C (36)
bi 765063 Colorectal Cancer	Boehringer Ingelheim	P1	C (36)
Bl-M17D1 Colorectal Cancer	Sichuan Baili Pharmaceutical Co., Ltd.	P1	C (36)
Bpi-442096 Colorectal Cancer	Betta Pharmaceuticals Co., Ltd.	P1	C (36)
Budigalimab Colorectal Cancer	AbbVie	P1	C (36)
Cadvec Colorectal Cancer	Baylor College of Medicine	P1	C (36)
Cbi-1214 Colorectal Cancer	Cartography Biosciences	P1	C (36)
Cea-Targeted Car-T Colorectal Cancer	Weijia Fang, MD	P1	C (36)
Certepetide Colorectal Cancer	University of California, San Diego	P1	C (36)
Clsp-5282 Colorectal Cancer	Clasp Therapeutics, Inc.	P1	C (36)
coq10 Colorectal Cancer	toqa saad mohammed mohammed	P1	C (36)
CRX100 Colorectal Cancer	BioEclipse Therapeutics	P1	C (36)
ct-202 Colorectal Cancer	Context Therapeutics Inc.	P1	C (36)
ct-95 Colorectal Cancer	Context Therapeutics Inc.	P1	C (36)
Dat-2645 Colorectal Cancer	Danatlas Pharmaceuticals Co., Ltd	P1	C (36)
Disp-10 Colorectal Cancer	Dispatch Biotherapeutics	P1	C (36)
dk210 Colorectal Cancer	DEKA Biosciences	P1	C (36)
Dp Cd8 Til Colorectal Cancer	AgonOx, Inc.	P1	C (36)
Drug: Ibi3028 Colorectal Cancer	Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.	P1	C (36)
Elvn-002 Colorectal Cancer	Enliven Therapeutics	P1	C (36)
ft536 Colorectal Cancer	Fate Therapeutics	P1	C (36)
ft836 Colorectal Cancer	Fate Therapeutics	P1	C (36)
[Ga-68]-Pnt6555 Colorectal Cancer	POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company	P1	C (36)
gh21 Colorectal Cancer	Suzhou Genhouse Bio Co., Ltd.	P1	C (36)
Hbi-2376 Colorectal Cancer	HUYABIO International, LLC.	P1	C (36)
Hbi-2438 Colorectal Cancer	HUYABIO International, LLC.	P1	C (36)
hfb200603 Colorectal Cancer	HiFiBiO Therapeutics	P1	C (36)
H-Gamma1 Heavy Chain Humanized (1-449) [Vh (Homo Sapiens Ighv3-2301 (81.6%) -(Ighd) -Ighj302 (91.7%) M123>T (114), Cdr-Imgt [8.7.13] (26-33.51-57.96-108)) (1-119) -Homo Sapiens Ighg103V (100%) G1M3>G1M17, Ng1M1 Ch1 K120, Ch3 E12, M14 (Ch1 R120>K (216) (120-217), Hinge 1-15 (218-232), Ch2 (233-342), Ch3 E12 (358), M14 (360) (343-447), Chs (448-449)) (120-449)], (222-218')-Disulfide With L-Kappa Light Chain Humanized (1'-218') [Vkappa (Homo Sapiens Igkv1-3301 (87.8%) -Igkj401 (100%), Cdr-Imgt [6.3.13] (27'-32'.50'-52'.89'-101')) (1'-111')-Homo Sapiens Igkc01 (100%) Km3 A45.1, V101 (C-Kappaa45.1 (157'), V101 (195')) (112'-218')]; Dimer (228-228'':231-231'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa Colorectal Cancer	Genentech, Inc.	P1	C (36)
hh160 Colorectal Cancer	Huahui Health	P1	C (36)
hs-10370 Colorectal Cancer	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P1	C (36)
hs-10502 Colorectal Cancer	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P1	C (36)
hs-20093 Colorectal Cancer	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P1	C (36)
hs-20117 Colorectal Cancer	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P1	C (36)
ibi351 Colorectal Cancer	Innovent Biologics (Suzhou) Co. Ltd.	P1	C (36)
Icovamenib Colorectal Cancer	Biomea Fusion Inc.	P1	C (36)
ide034 Colorectal Cancer	IDEAYA Biosciences	P1	C (36)
Ide-161 Colorectal Cancer	IDEAYA Biosciences	P1	C (36)
Idov-Immune Colorectal Cancer	ViroMissile, Inc.	P1	C (36)
ik-595 Colorectal Cancer	Ikena Oncology	P1	C (36)
im-1617 Colorectal Cancer	Immunome, Inc.	P1	C (36)
Imiquimod Colorectal Cancer	Toray Industries, Inc	P1	C (36)
imm2520 Colorectal Cancer	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	P1	C (36)
Immunoglobulin G1 [De-C-Terminal-Lysine], Anti-(Human Epidermal Growth Factor Receptor) (Human-Mus Musculus Clone Bca101 ?1-Chain), Disulfide With Human-Mus Musculus Clone Bca101 ?-Chain Fusion Protein With Peptide Linker (Ggggs)3 Fusion Protein With 23-159-Transforming Growth Factor ? Receptor Tgfbr2 (Human), Dimer Colorectal Cancer	Bicara Therapeutics	P1	C (36)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Tigit (T-Cell Immunoreceptor With Ig Domain And Itim, V-Set Ig Member 9, Vsig9, V-Set And Transmembrane Member 3, Vstm3)], Humanized Monoclonal Antibody; Gamma1 Heavy Chain Humanized (1-448) [Vh (Homo Sapiens Ighv3-4801 (90.8%) -(Ighd) -Ighj401 (92.3%)) Cdr-Imgt [8.8.12] (26-33.51-58.97-108) (1-119) -Homo Sapiens Ighg101, G1M17,1, G1V14 Ch2 A1.3, A1.2 (Ch1 K120 (216) (120-217), Hinge 1-15 (218-232), Ch2 L1.3>A (236), L1.2>A (237) (233-342), Ch3 D12 (358), L14 (360) (343-447), Chs K>Del (448)) (120-448)], (222-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-1601 (89.5%) -Igkj401 (100%)) Cdr-Imgt [6.3.9] (27-32.50-52.89-97) (1'-107') -Homo Sapiens Igkc01 (100%) Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (228-228'':231-231'')-Bisdisulfide, Produced In A Chinese Hamster Ovary (Cho)-K1 Cell Line, Glycoform Alfa Colorectal Cancer	Taiho Pharmaceutical Co., Ltd.	P1	C (36)
ivx037 Colorectal Cancer	ImmVirx Pty Ltd	P1	C (36)

Showing 551 to 600 of 714 assets

PreviousPage 12 of 15Next